Sun, Jan 25, 2015, 2:24 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Gilead Sciences Inc. Message Board

  • citamar citamar Jan 9, 2002 8:28 AM Flag

    Goldman Upgrades- Target $80

    Just what we needed this morning, an upgrade by Goldman. Put GILD on recommended list. Can anyone say $70 by the end of the week. This stock is incredible!

    7:51AM Gilead Sciences (GILD) 63.84: Goldman Sachs upgrades to RECOMMENDED LIST from Mkt Outperform, based valuation and strong 2002 sales prospects, solid pipeline, and nearing profitability; key growth driver will be Viread. Firm maintains $75-$80 price target.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Basically since John Martin all but said that Tenofovir sales won't be a disaster, that's enough to get the stock up a few bucks.

      Tells you how much event risk on a Tenofovir sales dissapointment the market was pricing in.

      The other risk of course is if GILD takes over another biotech firm with a (relatively) large market cap. I'd say anything over a $600M acquisition would affect GILD's stock price.

      Implied volatility is low, this still suggests that GILD is going to be trading in the 60-70 dollar band. Selling one-month at the money covered when/if the common stock hits 70-71 bucks might be the viable strategy. We'll see how it unfolds.

105.54+0.4000(+0.38%)Jan 23 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.